Meril Life Sciences, a leading global med-tech company with its portfolio in cardiovascular and structural heart solutions, celebrated a remarkable achievement with the launch of its cutting-edge Myval Octapro Transcatheter Heart Valve (THV) at GISE 2024 (National Congress of the Italian Society of Interventional Cardiology) and PCR London Valves 2024.

Meril Life Sciences是一家领先的全球医学技术公司，拥有心血管和结构性心脏解决方案的投资组合，在GISE 2024（意大利介入心脏病学会全国代表大会）和PCR London Valves 2024上推出了其尖端的Myval Octapro经导管心脏瓣膜（THV），以庆祝其取得的非凡成就。

These prestigious global conferences provided the perfect stage for Meril to reinforce its unwavering commitment to transforming structural heart care..

这些久负盛名的全球会议为梅里尔提供了一个完美的舞台，以加强其对结构性心脏护理的坚定不移的承诺。。

The launch of the Myval Octapro THV introduces lowframe foreshortening for enhanced operator control and precise deployment, making procedures more predictable and effective. It also offers an extensive size matrix, including conventional, intermediate, and extra-large valve sizes, ensuring optimal bioprosthetic valve sizing tailored to individual patient needs..

Myval Octapro THV的推出引入了低帧缩短技术，以增强操作员控制和精确部署，使程序更具可预测性和有效性。它还提供了广泛的尺寸矩阵，包括传统的，中等的和超大的瓣膜尺寸，确保根据患者的需求量身定制最佳的生物瓣膜尺寸。。

The unveiling of the Myval Octapro THV at GISE 2024 and PCR London Valves 2024 marked more than a product launch. It is a testament to Meril’s mission to advance structural heart care through collaboration and innovation. In response, the worldwide healthcare community hailed Meril for their latest innovations..

Myval Octapro THV在GISE 2024和PCR London Valves 2024上的推出标志着不仅仅是产品发布。这证明了梅里尔通过合作和创新推进结构性心脏护理的使命。作为回应，全球医疗保健界盛赞梅里尔的最新创新。。

Dr. Ashok Seth, Chairman of Fortis Escorts Heart Institute and Fortis Healthcare Medical council, Delhi, “Congratulations to Meril Life Sciences on the launch of the novel MyvalOctapro. We are proud Meril has been consistently innovating to set fresh benchmarks in Transcatheter structural therapies as well as proving them to be safe and effective through well conducted perspective randomised studies.

德里富通护卫心脏研究所和富通医疗保健委员会主席Ashok Seth博士表示，“祝贺Meril Life Sciences推出新型MyvalOctapro。我们很自豪Meril一直在创新，为经导管结构疗法设定新的基准，并通过良好的前瞻性随机研究证明它们是安全有效的。

Octapro THV is next-generation balloon expandable valve minimal foreshortening to enable precise deployment and commisural alignment Furthermore, the nine valve sizes (which includes intermediate sizing and extra-large size) enables accurate and appropriate fit to patient’s anatomy. In fact, approx.

Octapro THV是下一代球囊扩张瓣膜，可实现最小的缩短，以实现精确的部署和共面对齐。此外，九种瓣膜尺寸（包括中等尺寸和超大尺寸）可准确且适当地适合患者的解剖结构。事实上，大约。

50% of Myval THV series implants are intermediate-sized devices, which gives operators a wider options to all possible annular anatomies”..

Myval THV系列植入物中有50%是中等尺寸的装置，这为操作者提供了更广泛的选择，以实现所有可能的环形解剖结构”。

At London Valves 2024, Meril presented new data from the LANDMARK trial’s subset analysis, complementing its earlier publication in The Lancet. This detailed analysis, now published in the renowned EuroIntervention journal, further reinforces the safety and efficacy of the Myval THV series compared to the Sapien and Evolut THV series..

在2024年伦敦阀门展上，梅里尔提供了里程碑式试验子集分析的新数据，补充了早期在《柳叶刀》上发表的数据。这项详细的分析现已发表在著名的欧洲干预杂志上，与Sapien和Evolut THV系列相比，进一步加强了Myval THV系列的安全性和有效性。。

Mr. Sanjeev Bhatt, Senior Vice President of Corporate Strategy at Meril Life Sciences, expressed gratitude and optimism by saying, “The positive reception of the Myval Octapro THV at these global platforms underscores our commitment to delivering cutting-edge solutions for severe aortic stenosis. We are proud to collaborate with clinicians worldwide in advancing TAVR technology and improving patient outcomes through innovation.”.

Meril Life Sciences公司战略高级副总裁Sanjeev Bhatt先生表示感谢和乐观，他说：“Myval Octapro THV在这些全球平台上的积极接受突显了我们对为严重主动脉瓣狭窄提供尖端解决方案的承诺。我们很自豪与全球临床医生合作，推进TAVR技术，并通过创新改善患者预后。”。

The results highlighted comparable composite safety and effectiveness outcomes between Myval and Sapien (24.7% vs. 24.1%), with Myval demonstrating a lower rate of permanent pacemaker implantation (15.0% vs. 17.3%) and superior hemodynamic performance. Similarly, the Myval THV series performed on par with Evolut in composite endpoints (24.7% vs.

结果显示，Myval 和 Sapien 的综合安全性和有效性结果相当（24.7% 对 24.1%），Myval 的永久起搏器植入率更低（15.0% 对 17.3%），血液动力学性能更优越。同样，Myval THV 系列在综合终点方面的表现与 Evolut 相当（24.7% 对 24.1%）。

30%), while showing advantages in reducing pacemaker implantation rates and moderate/severe valve regurgitation. Effective orifice areas were also comparable between 26 and 29 mm of Myval THV series and Evolut THV series, underscoring its strong performance in key clinical measures..

30%），同时在降低起搏器植入率和中度/重度瓣膜返流方面显示出优势。Myval THV系列和Evolut THV系列的有效孔口面积在26至29 mm之间也具有可比性，突显了其在关键临床措施中的强大表现。。

In the small aortic annulus cohort, Myval outperformed Sapien in hemodynamics and showed fewer clinical events than Evolut, despite Evolut’s superior hemodynamic performance. These findings underscore Myval’s pivotal role in advancing TAVR technology across diverse patient groups.

在小主动脉环队列中，尽管Evolut具有优越的血流动力学性能，但Myval在血流动力学方面优于Sapien，并且显示出比Evolut更少的临床事件。

As the Myval Octapro THV begins its journey of clinical impact, Meril remains steadfast in its commitment to alleviating human suffering and enhancing the quality of life through groundbreaking medical technologies.

随着Myval Octapro THV开始其临床影响之旅，Meril仍然坚定地致力于通过开创性的医疗技术减轻人类痛苦并提高生活质量。